Black Diamond Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Main St Ste 14, Cambridge, Massachuset...Phone Number
(617) 252-0848Revenue
-Stock Symbol
BDTXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform and drug discovery engine, the Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy.Explore more
Black Diamond Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Black Diamond Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Black Diamond Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Black Diamond Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Black Diamond Therapeutics launches new products
Check out if Black Diamond Therapeutics is spiking on competitors!
Click to see if Black Diamond Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Black Diamond Therapeutics recently announced quarterly report
Check if Black Diamond Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Black Diamond Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Black Diamond Therapeutics
Compare insights from companies similar to Black Diamond Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Black Diamond Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Black Diamond Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Black Diamond Therapeutics.
Black Diamond Therapeutics financials insights
Gather financial insights about Black Diamond Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$20M
2019
Series B
$85M
Series C
$85M
2020
Stock Offering
$231M
Black Diamond Therapeutics Tech Stack
A closer look at the technologies used by Black Diamond Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Black Diamond Therapeutics has initiated a randomized Phase II trial of BDTX-1535 in combination with standard-of-care temozolomide versus temozolomide alone in newly diagnosed glioblastoma patients following surgery and chemoradiation, with the first cohort already enrolled and data expected in H1 2028.
Medical Research, Pharmaceuticals, Clinical Operations
Project
plans to request an FDA meeting in Q3, with feedback expected in early Q4, to determine the fastest regulatory approval path for silevertinib, including potential strategies such as a randomized trial for patients with CNS disease at diagnosis and a single-arm path for patients with PACC mutations.
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Events
Person-Based
Medical Research, Pharmaceuticals
Black Diamond Therapeutics News & Media
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors onBlack Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., ClinBlack Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Black Diamond Therapeutics
Sign Up For FreeTo access detailed company insights
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's propr... Read More
